Bispecifics and T cell Engagers

Wednesday, Feb. 25, 2026 |1–5 p.m. ET
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of bispecifics and T cell engagers for hematologic malignancies and solid tumors. FREE for healthcare professionals, students, patients and patient advocates. 

  • Discuss current and emerging bispecifics for hematologic malignancies and solid tumors.

  • Address toxicities and adverse events associated with these emerging agents and special considerations when implementing bispecifics and T cell engagers in the outpatient setting.

This ACI program is supported, in part by, (as of Jan. 16, 2026):

Program Organizers

Sid Devarakonda, MD Swedish Cancer Institute

Sid Devarakonda, MD
Swedish Cancer Institute

Megan May, PharmD, BCOP, FHOPA, FAPO Baptist Health System

Megan May, PharmD, BCOP, FHOPA, FAPO
Baptist Health System

Program Agenda

1–1:05 p.m. Welcome
1:05–1:50 p.m. Primer on Bispecifics & Current and Emerging Bispecifics for Solid Tumors
Jeff Ward, MD, PhD – Washington University School of Medicine
1:50–2:10 p.m. Current and Emerging Bispecifics for Lymphoma
Swathi Namburi, MD – Swedish Cancer Institute
2:10–2:30 p.m. Current and Emerging Bispecifics for Multiple Myeloma 
Brooke Adams, PharmD, BCOP – Orlando Health
2:30–2:50 p.m. Current and Emerging Bispecifics for Leukemia
Elias Jabbour, MD – MD Anderson Cancer Center
2:50–3:05 p.m. Q&A
3:05–3:20 p.m. Break (15 minutes)
3:20–3:40 p.m. Bispecifics in Practice: irAEs and Toxicities
Zachary Crees, MD – Washington University School of Medicine
3:40–4 p.m. Bispecifics in Practice: Patient Education and Implementation in Out-Patient Setting
Emillie Aschenbrenner, PharmD, BCOP – Froedtert & Medical College of Wisconsin
4–5 p.m. Faculty Panel 
5 p.m. Closing Remarks

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to onlineeducation@sitcancer.org.

Program Learning Objectives

  • Describe the mechanisms of bispecific antibodies and T cell engagers.
  • Summarize recent updates in the clinical use of T cell engagers, including the recent approvals of T cell engagers for solid tumors.
  • Outline common toxicities with T cell engagers and common approaches to managing these toxicities and compare these toxicities and their management to those associated with cellular therapies.
  • Identify unique institutional resources required for the appropriate use of bispecific antibodies and T cell engagers, especially in out-patient and community hospital settings.